WASHINGTON, Sept. 18 -- Food and Drug Administration has issued a notice called: Fee Rate for Using a Priority Review Voucher in Fiscal Year 2026.
The notice was published in the Federal Register on Sept. 18 by Grace R. Graham, Deputy Commissioner for Policy, Legislation, and International Affairs.
Summary: The Food and Drug Administration (FDA or the Agency) is announcing the fee rate for using a priority review voucher for fiscal year (FY) 2026. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended, authorizes FDA to determine and collect priority review user fees for certain applications for review of human drug or biological products when those applications use a tropical disease, rare pediatric disease, or material threat m...